Trials / Completed

CompletedNCT00732771

Proof-of-concept for the Aldosterone Synthase Inhibitor LCI699 in Patients With Primary Hyperaldosteronism

A Pilot, Single-blind, Forced-titration Study to Assess the Hemodynamic and Hormonal Effects, Safety and Tolerability of the Aldosterone Synthase Inhibitor LCI699 in Patients With Primary Hyperaldosteronism

Status: Completed
Phase: Phase 2
Study type: Interventional
Enrollment: 12 (estimated)

Sponsor: Novartis · Industry
Sex: All
Age: 18 Years – 70 Years
Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine if LCI699, thorough reductions in aldosterone, can lower BP in patients with Primary hyperaldosteronism.

Conditions

Primary Hyperaldosteronism

Interventions

Type	Name	Description
DRUG	LCI699

Timeline

Start date: 2008-06-01
Primary completion: 2009-05-01
First posted: 2008-08-12
Last updated: 2009-08-26

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT00732771. Inclusion in this directory is not an endorsement.